This blog is not affiliated or endorsed, by Nassau OTB, a public benefit corporation, subject to the New York Freedom
of Information Law, NY Pub Off Law Sec 84 et seq.
Nassau County's off-track betting
agency has eliminated Plainview as a potential location for video
gambling terminals because of opposition from town and community
leaders.
The Nassau Regional Off-Track Betting
Corporation, also known as Nassau Downs OTB, sent notice of the decision
in a Jan. 31 letter to Town of Oyster Bay Supervisor John Venditto.
OTB general counsel Arthur Walsh said
the county's authorized 1,000 video gaming devices "will not be sited at
its Plainview tele-theater," the Race Palace on Round Swamp Road just
south of the Long Island Expressway. RESULTS: Votes totals in all races DATA:Contributions in Nassau Executive race | Contributions in NYC Mayor's race MORE:Full coverage
"This decision is based on multiple factors,
particularly your forceful advocacy on behalf of residents living in the
vicinity," Walsh wrote.
Venditto said Monday that "Nassau OTB . . . should be commended for acting as a good neighbor."
"It's not something that belongs in a
suburban community," said Carol Meschkow, president of the Concerned
Citizens of the Plainview-Old Bethpage Community. She said her
association had lobbied town and county officials, and it collected
about 700 signatures on a petition.
Meschkow said that within a two-mile
radius of the betting site, there was an elementary school, middle
school and high school. "To me it was a recipe for disaster," she said.
Ginger Lieberman, president of the
Plainview-Old Bethpage Board of Education, said, "This is something that
the community is going to be very relieved about."
She said there are many homes nearby
on Round Swamp Road and Old Country Road with a major development
proposed at the intersection of those two roads.
Nassau and Suffolk officials are
working on locations for 1,000 slot machines each, the first on Long
Island. The state in June granted each county permission to operate
video lottery terminals.
Nassau OTB president Joseph Cairo said
in December that he hoped to open a facility in 2015. He added that
while the Race Palace was a possible location, he was concerned about
its limited parking and opposition from the community.
Cairo also said the location was not
ideal because it was close to Suffolk County and he did not want to
compete with its parlor.
To evaluate Bacille Calmette-Guérin (BCG) effects after clinically isolated syndromes (CIS).
METHODS:
In a double-blind, placebo-controlled trial, participants were randomly assigned to receive BCG
or placebo and monitored monthly with brain MRI (6 scans). Both groups
then entered a preplanned phase with IM interferon-β-1a for 12 months.
From month 18 onward, the patients took the disease-modifying therapies
(DMTs) that their neurologist considered indicated in an open-label
extension phase lasting up to 60 months.
RESULTS:
Of 82
randomized subjects, 73 completed the study (33 vaccinated and 40
placebo). During the initial 6 months, the number of cumulative lesions
was significantly lower in vaccinated people. The relative risks were
0.541 (95% confidence interval [CI] 0.308-0.956; p = 0.03) for
gadolinium-enhancing lesions (the primary endpoint), 0.364 (95% CI
0.207-0.639; p = 0.001) for new and enlarging T2-hyperintense lesions,
and 0.149 (95% CI 0.046-0.416; p = 0.001) for new T1-hypointense
lesions. The number of total T1-hypointense lesions was lower in the BCG
group at months 6, 12, and 18: mean changes from baseline were -0.09 ±
0.72 vs 0.75 ± 1.81 (p = 0.01), 0.0 ± 0.83 vs 0.88 ± 2.21 (p = 0.08),
and -0.21 ± 1.03 vs 1.00 ± 2.49 (p = 0.02). After 60 months, the
cumulative probability of clinically definite multiple sclerosis was
lower in the BCG
+ DMT arm (hazard ratio = 0.52, 95% CI 0.27-0.99; p < 0.05), and
more vaccinated people remained DMT-free (odds ratio = 0.20, 95% CI
0.04-0.93; p = 0.04).
CONCLUSIONS:
Early BCG may benefit CIS and affect its long-term course.
CLASSIFICATION OF EVIDENCE:
BCG,
as compared to placebo, was associated with significantly reduced
development of gadolinium-enhancing lesions in people with CIS for a
6-month period before starting immunomodulating therapy (Class I
evidence).
No
targeted immunotherapies reverse type 1 diabetes in humans. However, in
a rodent model of type 1 diabetes, Bacillus Calmette-Guerin (BCG)
reverses disease by restoring insulin secretion. Specifically, it
stimulates innate immunity by inducing the host to produce tumor
necrosis factor (TNF), which, in turn, kills disease-causing autoimmune
cells and restores pancreatic beta-cell function through regeneration.
METHODOLOGY/PRINCIPAL FINDINGS:
Translating these findings to humans, we administered BCG,
a generic vaccine, in a proof-of-principle, double-blind,
placebo-controlled trial of adults with long-term type 1 diabetes (mean:
15.3 years) at one clinical center in North America. Six subjects were
randomly assigned to BCG
or placebo and compared to self, healthy paired controls (n = 6) or
reference subjects with (n = 57) or without (n = 16) type 1 diabetes,
depending upon the outcome measure. We monitored weekly blood samples
for 20 weeks for insulin-autoreactive T cells, regulatory T cells
(Tregs), glutamic acid decarboxylase (GAD) and other autoantibodies, and
C-peptide, a marker of insulin secretion. BCG-treated
patients and one placebo-treated patient who, after enrollment,
unexpectedly developed acute Epstein-Barr virus infection, a known TNF
inducer, exclusively showed increases in dead insulin-autoreactive T
cells and induction of Tregs. C-peptide levels (pmol/L) significantly
rose transiently in two BCG-treated
subjects (means: 3.49 pmol/L [95% CI 2.95-3.8], 2.57 [95% CI
1.65-3.49]) and the EBV-infected subject (3.16 [95% CI 2.54-3.69])
vs.1.65 [95% CI 1.55-3.2] in reference diabetic subjects. BCG-treated
subjects each had more than 50% of their C-peptide values above the
95(th) percentile of the reference subjects. The EBV-infected subject
had 18% of C-peptide values above this level.
CONCLUSIONS/SIGNIFICANCE:
We conclude that BCG
treatment or EBV infection transiently modified the autoimmunity that
underlies type 1 diabetes by stimulating the host innate immune
response. This suggests that BCG or other stimulators of host innate immunity may have value in the treatment of long-term diabetes.
Parkinson'sdisease (PD) is a motor disease
including disorders of mobility, fine tremor, rigidity and posture
caused by a relentless deterioration of dopaminergic cells in the
substantia nigra (SN). Disorders of affect and a range of other symptoms
including fatigue, cognitive dysfunction and mental confusion, sleep
disorder and addictions are also seen as other CNS sites are also
affected. Idiopathic
and genetic causes together with inflammatory and degenerative
disorders of ageing have been postulated as contributing to PD.
Autoimmunity affecting certain vasoactive neuropeptides (VNs) has been
postulated as contributing to certain fatigue-related conditions in
humans and may be consistent with compromise of receptors associated
with VNs and including receptors for vasoactive intestinal polypeptide
(VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP).
Pro-inflammatory responses are seen in PD patients consistent with
apoptotic neurodegeneration. Involvement of the Th1 directed cytokine
interferon-gamma has been demonstrated and Th2 directed cytokines such
as IL-10 protect against inflammation-mediated degeneration of
dopaminergic neurons in the SN. Nitric-oxide dysregulation is also
postulated in PD by fostering dopamine depletion via nitric-oxide
synthase (iNOS). Both PACAP and VIP have neuroprotective effects in PD
models by inhibiting the production of inflammatory mediators. PACAP
specifically protects against the neurotoxicity induced by rotenone as
well as protecting against oxidative stress-induced apoptosis. These
findings suggest that a defect in VN function may act adversely on SN
cells and hence contribute to a clinical presentation consistent with
PD. The conclusion drawn from these findings is that PD may be an autoimmune
disorder of VNs, specifically PACAP and VIP. Possibly unusual or
anatomically specific receptors for these VNs may be involved. If
proven, this hypothesis would have significant implications for
immunological and pharmacological treatment and prevention of PD.
1. Cancer patients should read of aspirin and metformin and upon failing to be treated at Yale and seeing the grim reaper draw nigh, swallow the combination of aspirin and metformin in quantities as desired and record the results. Simple, safe, cheap and effective, this combination with a rational basis in the scientific literature.
Try it you'll like it. Dying people may make data. You will never see dope companies testing this combination or disclosing the data that it works, saves lives and costs little.
2. I will be glad to show you on You Tube that a single vaccination does of BCG reduces erythema and plaque thickness of plaque psoriasis. The effect does not seem to last long. Further data and experimentation is needed. See faustmanlab.org and pubmed.org for reasons to expect this effect.
3. MS patients may take the heat challenge. Find an MS patient, inject same with BCG, wait or observe over time and record on You Tube. To add insult to injury, heat the subject in any many desired which will usually produce an undesired effect(s). BCG will mitigate MS and you may record the data as desired on
You Tube.
Not all data need to generated in perfect form or by data doers. A little common sense and application of teachings may go a long way.
Yale and Harvard are both bum places to seek treatment for causalgia.
A careful study of the treatment of Mrs. J Edward Spike Jr. as observed by her personal physician Mark
Altshule of Harvard and found at The Lancet p106 Janl. 14, 1978 will enable almost anyone to treat a
wide(r) variety of conditions. Simply match your test subject with the description of Mrs. Spike found in The Lancet and voila, you will be able to do them some good.
4. Got ALS and want to bet that there is a previously unknown pathology in cases of ALS?
I will be glad to indentify where you will find same. The pathology may be readily obtained from a cadaver or a living human being with ALS.
LAST
week, Johnson & Johnson announced that it was making all of its
clinical trial data available to scientists around the world. It has
hired my group, Yale University
Open Data Access Project, or YODA, to fully oversee the release of the
data. Everything in the company’s clinical research vaults, including
unpublished raw data, will be available for independent review.
This
is an extraordinary donation to society, and a reversal of the
industry’s traditional tendency to treat data as an asset that would
lose value if exposed to public scrutiny.
Today, more than half of the clinical trials
in the United States, including many sponsored by academic and
governmental institutions, are not published within two years of their
completion. Often they are never published at all. The unreported
results, not surprisingly, are often those in which a drug failed to
perform better than a placebo. As a result, evidence-based medicine is,
at best, based on only some of the evidence. One of the most troubling
implications is that full information on a drug’s effects may never be
discovered or released.
Even
when studies are published, the actual data are usually not made
available. End users of research — patients, doctors and policy makers —
are implicitly told by a single group of researchers to “take our word
for it.” They are often forced to accept the report without the prospect
of other independent scientists’ reproducing the findings — a violation
of a central tenet of the scientific method.
To
be fair, the decision to share data is not easy. Companies worry that
their competitors will benefit, that lawyers will take advantage, that
incompetent scientists will misconstrue the data and come to mistaken
conclusions. Researchers feel ownership of the data and may be reluctant
to have others use it. So Johnson & Johnson, as well as companies
like GlaxoSmithKline and Medtronic
that have made more cautious moves toward transparency, deserve much
credit. The more we share data, however, the more we find that many of
these problems fail to materialize.
In
2011, YODA struck a deal with Medtronic to release all the data on one
of its products — a device that stimulates the production of bone. At
the time, questions had been raised about the device’s safety, including
whether it caused cancer,
and about the conflicts of interests of some of the company’s
researchers. Medtronic made the unusual decision to respond to the
debate by releasing the device’s data for independent review. We
commissioned and then published two independent reviews of the data, and
now have made them globally available.
Interestingly, the reviews produced somewhat conflicting results. One found that the device was no better than a bone graft
and might be associated with a slight increase in cancer, while the
other found that the device was effective and the cancer risk
inconclusive. To us these differences reinforce the value of open
science: now the data are out there for further study.
This
program doesn’t mean that just anyone can gain access to the data
without disclosing how they intend to use it. We require those who want
the data to submit a proposal and identify their research team, funding
and any conflicts of interest. They have to complete a short course on
responsible conduct and sign an agreement that restricts them to their
proposed research question. Most important, they must agree to share
whatever they find. And we exclude applicants who seek data for
commercial or legal purposes. Our intent is not to be tough gatekeepers,
but to ensure that the data are used in a transparent way and
contribute to overall scientific knowledge.
There
are many benefits to this kind of sharing. It honors the contributions
of the subjects and scientists who participated in the research. It is
proof that an organization, whether it is part of industry or academia,
wants to play a role as a good global citizen. It demonstrates that the
organization has nothing to hide. And it enables scientists to use the
data to learn new ways to help patients. Such an approach can even teach
a company like Johnson & Johnson something it didn’t know about its
own products.
For the good of society, this is a breakthrough that should be replicated throughout the research world.
Harlan M. Krumholz is a professor of cardiology and public health at the Yale School of Medicine.
Five years, two articles in this space, assistance from the Labor Department and the Internal Revenue Service and prodding from one no-nonsense bankruptcy judge — that’s what it took for owners of the 401(k) plan sponsored by Penn Specialty Chemicals to gain access to their money last month.
Finally,
these 401(k) holders have been released from the limbo where they’d
been trapped since their company filed for bankruptcy in December 2008.
While
such fiascos don’t occur everyday, the Penn Specialty Chemicals 401(k)
case shows what can happen to account holders if their company
collapses. It’s not a pretty picture.
When
a company goes bankrupt, the assets of its 401(k) are supposed to be
transferred to account holders promptly. But that didn’t happen here.
After
the bankruptcy filing by Penn Specialty, a chemicals maker based in
Memphis, its 401(k) holders were not only frozen out of their funds for
five years, but were also charged significant fees for administrative
and legal work during that time. Some of the participants even faced tax
penalties because they couldn’t withdraw some of their money at age 70
1/2, as tax law requires.
Launch media viewer
Minh Uong/The New York Times
George
L. Miller, a certified public accountant at Miller Coffey Tate in
Philadelphia, was appointed trustee by the bankruptcy court to oversee
the Penn Specialty 401(k). For years, he told plan participants that the
I.R.S. had not issued a so-called determination letter that would have
allowed the plan’s assets to be distributed.
But
it wasn’t clear why the I.R.S. would object. The I.R.S. manual notes
that bankruptcy is usually enough evidence to support a plan’s
termination and payout.
Fees
for administration of the 401(k), meanwhile, piled up. During 2009 and
2010, for example, fees of $111,463 were charged, or 2.8 percent of the
plan’s roughly $4 million in employee assets.
The
fees went to the overseers of the plan — Mr. Miller and a consulting
firm in Melville, N.Y., called the Comprehensive Consulting Group. But
in 2011, Vanguard, the plan’s record keeper, stopped paying the
overseers after receiving what it said were unsatisfactory answers to
questions it had asked about the delays in paying out participants.
Calls to Mr. Miller and to the Comprehensive Consulting Group last week were not returned.
Shankar Iyer, 72, was principal scientist at Penn A Kem,
a European chemicals company that acquired some of the operations of
Penn Specialty before it folded. After a year of waiting to get at his retirement
account, Mr. Iyer began asking the trustee, the I.R.S. and the Labor
Department what was taking so long. He took up the fight to unlock the
401(k) for himself and for the roughly 40 other participants in the
plan.
In
2012, the Labor Department opened an investigation into the case. This
seemed to annoy Mr. Miller, who Mr. Iyer said told him that involving
Labor Department officials would result in an even longer wait and
additional costs for plan participants.
Mr.
Iyer, who has glaucoma and diabetes, retired last fall. He said he
continued working far longer than planned because he could not withdraw
any of his retirement savings — 41 years’ worth that he had earned at a
variety of companies but had rolled over into his Penn Specialty
account. He was also upset by the $49,728 in administrative and legal
fees extracted from his account while it was in limbo. Those fees ranged
from 1.5 percent to 3.75 percent of his account’s balance when they
were charged.
On
Jan. 24, 2013, the I.R.S. sent a determination letter to Comprehensive
Consulting, stating that the plan’s assets could be distributed to
participants.
Even
that did not end Mr. Iyer’s battle. When he telephoned Comprehensive
Consulting to ask for his money, he said, he was told that it had not
received the letter, which an official at the I.R.S. confirmed it had
sent.
Finally,
last August, an exasperated Mr. Iyer wrote a letter seeking help from
Brendan Linehan Shannon, the federal bankruptcy judge in the district of
Delaware who oversaw the Penn Specialty bankruptcy years earlier. On
Sept. 5, the judge called Mr. Miller and other interested parties to a
hearing in his chambers 11 days later. A lawyer for the Labor Department
attended; Mr. Iyer was patched in by telephone from Tennessee. Two
lawyers representing Mr. Miller, the trustee, were also there; they said
the delay was the fault of the Labor Department. The judge directed the
trustee to resolve the matter within two months.
That
deadline passed with no payout. On Nov. 26, Mr. Iyer advised the judge,
who ordered Mr. Miller’s lawyer to resolve the case within a week.
In
early December, Mr. Iyer and all the plan participants finally received
word that the money was on its way. After five years, one month and 11
days, Mr. Iyer’s funds were released in mid-January.
“I
got most of my money but I lost quite a bit,” Mr. Iyer said. “It is
interesting to note that the fees I ended up paying exceed what Penn
Specialty Chemicals contributed on my account. I have learned never to
trust a 401(k).”
Who
knows how long the Penn Specialty employees might have had to wait,
were it not for the help of Judge Shannon and two federal agencies? And
who knows how much the participants would have paid if Vanguard had not
intervened on their behalf?
We
do know, from Jason Surbey, a spokesman at the Labor Department, that
the fees charged to the plan would have been larger had it not pushed
the trustee to reduce what he sought to charge the plan.
Americans
increasingly must rely on 401(k) plans to support themselves when they
have finished their working lives. You can’t help wondering: Is this any
way to run a retirement system?
WHAT: Meeting of the New York Task Force on Jockey Health and Safety
WHEN: Thursday, February 6, 2014 at 1 p.m.
WHERE: Physicians Reciprocal Insurers
1800 Northern Blvd
Roslyn, NY 11576
This meeting will be open to the public.
Members of the public or media wishing to attend
the meeting must RSVP by 3 p.m. on Wednesday, February 5 by calling
516-277-4010. All attendees must have valid photo ID to be admitted into
the building.
to Montana to help. He will stop beating on non-Catholics and see that Nassau OTB is open 365 days of the year without religious preference and he will earmark the proceeds from the betting that occurs only on Roman Catholic Palm Sunday and Roman Catholic Easter Sunday to Montana to help with the cause. Cuomo is King of NY and he can't file for bankruptcy but he can see that New York State runs out of cash.
The Roman Catholic Diocese of Helena filed
for Chapter 11 bankruptcy protection Friday afternoon in an effort to
resolve more than 350 sexual-abuse claims.
The
diocese listed assets between $1 million and $10 million and
liabilities between $10 million and $50 million in its bankruptcy
petition, filed with the U.S. Bankruptcy Court in Butte, Mont.
The
Chapter 11 filing follows a mediation process that resulted in a
settlement with insurers and the individuals who have brought sexual
abuse claims against the diocese.
"Once
the reorganization proceedings conclude, we will be able to plan
confidently for future ministry for the people of the Church of the
Diocese of Helena,"
Helena Bishop George Leo Thomas
said Friday in a statement.
Should
a bankruptcy judge approve the settlement, the diocese would pay $15
million to currently identified holders of sexual-abuse claims with
additional funding set aside for others who may come forward with abuse
claims in the future.
The majority of
the proposed settlement would be funded by the diocese's insurers,
though the diocese estimates it would pay at least $2.5 million to fund
claims and legal costs.
Most of the 362
claims that have been brought against the diocese allegedly took place
between 30 and 60 years ago, according to the news release.
"On
behalf of the entire Diocese of Helena, I express my profound sorrow
and sincere apologies to anyone who was abused by a priest, a sister, or
a lay Church worker," Bishop Thomas said. "No child should experience
harm from anyone who serves in the Church."
Ten
other U.S. dioceses have turned to bankruptcy protection since 2004 to
deal with the financial difficulties of sexual-abuse litigation; most
recently, Stockton, Calif., and Gallup, N.M., have filed bankruptcy
petitions.
Through 2012, the Catholic
Church in the U.S. paid an estimated $2.2 billion to cover settlements,
therapy for victims, support for offenders, attorney fees and other
costs, according to a report by the U.S. Conference of Catholic Bishops.
is NO CALENDAR CUOMO HE WANTS TO BE KING EXPORT ANDREW CUOMO NOW
Dear Fellow New Yorker, Today, families and friends across the
state will gather to celebrate the eve of a momentous holiday in the
Asian community. January 31st marks the arrival of the Lunar New Year
when we will welcome the Year of the Horse. During this joyous celebration, members
of New York’s large and vibrant Asian community will take the
opportunity to pay respect to their elders and ancestors, spend time
with family, give thanks, and look forward to a new year filled with
luck, happiness and prosperity. In New York, this special occasion is
celebrated by a variety of festivals, parades, and joyful gatherings
that preserve and enrich a proud heritage. My best wishes to all of those celebrating the Lunar New Year for a peaceful, healthy and successful new year. Sincerely,
This is a message from the New York State Executive Chamber, State Capitol, Albany, NY 12224.
Stop scratching on holidays
Published: June 1, 2012
Off Track Betting in New
York State has been racing into a crisis called shrinking
revenue. Some people have spitballed a solution: Don’t close
on holidays. New York State Racing Law
bars racing on Christmas, Easter and Palm Sunday, and the
state has ruled OTBs can’t handle action on those days, even
though they could easily broadcast races from out of state. “You should be able to bet whenever
you want,” said Jackson Leeds, a Nassau OTB employee who
makes an occasional bet. He added some irrefutable logic:
“How is the business going to make money if you’re not open
to take people’s bets?” Elias Tsekerides, president of the
Federation of Hellenic Societies of Greater New York,
said OTB is open on Greek Orthodox Easter and Palm Sunday. “I don’t want discrimination,”
Tsekerides said. “They close for the Catholics, but open for
the Greek Orthodox? It’s either open for all or not open.” OTB officials have said they lose
millions by closing on Palm Sunday alone, with tracks such
as Gulfstream, Santa Anita, Turf Paradise and Hawthorne
running. One option: OTBs could just stay
open and face the consequences. New York City OTB did just
that back in 2003. The handle was about $1.5 million – and
OTB was fined $5,000. Easy money.
NY CONST ART 1 SEC 3 IS WRITTEN IN CHINESE FOR ANDREW CUOMO